Previous 10 | Next 10 |
home / stock / etnb / etnb articles
RBC Capital Markets downgraded 89Bio Inc (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on developing and commerc...
U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CX...
89bio Inc (NASDAQ: ETNB) announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in...
SAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the developmen...
Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxiferm...
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. SMX (Security Matters) Public Limited Company (NAS...
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s sess...
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow tr...
SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the developme...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...